Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Share :
Published: 25 Jun 2021
Views: 3906
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

Prof Cristina Gasparetto speaks to ecancer about the efficacy of once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multiple myeloma (MM) patients.

Initially, she explains the background of this study. Prof Gasparetto then talks about the methodology and key results of this study.

In patients with heavily pretreated MM, weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 48%) with an overall PFS of 23 months. All AEs, including grade 3/4 thrombocytopenia, can be managed with appropriate supportive care and dose modifications.

These data support further investigation of XKd in patients with previously treated MM including those with prior daratumumab treatment.

In the end, she discusses the impact the results from this study can have on the future treatment of multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.